ALVR (AlloVir) Dividends per Share : $0.00 (TTM As of Dec. 2024)

View and export this data going back to 2020. Start your Free Trial

What is AlloVir Dividends per Share?

AlloVir's dividends per share for the three months ended in Dec. 2024 was $0.00. Its dividends per share for the trailing twelve months (TTM) ended in Dec. 2024 was $0.00. Its Dividend Payout Ratio for the three months ended in Dec. 2024 was 0.00. As of today, AlloVir's Dividend Yield % is 0.00%.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average dividends per share growth rate.

For more information regarding to dividend, please check our Dividend Page.

* Please note that "special dividend" is not included in the calculation of dividend per share and related fields.

AlloVir Dividends per Share Historical Data

The historical data trend for AlloVir's Dividends per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

AlloVir Dividends per Share Chart

AlloVir Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Dividends per Share

Get a 7-Day Free Trial

AlloVir Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Dividends per Share	Get a 7-Day Free Trial															-	-	-	-	-

Competitive Comparison of AlloVir's Dividends per Share

For the Biotechnology subindustry, AlloVir's Dividend Yield %, along with its competitors' market caps and Dividend Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

AlloVir's Dividend Yield % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, AlloVir's Dividend Yield % distribution charts can be found below:

* The bar in red indicates where AlloVir's Dividend Yield % falls into.

Save Embed

;

Save Embed

;

AlloVir Dividends per Share Calculation

Dividends paid to per common share.

AlloVir (NAS:ALVR) Dividends per Share Explanation

1. Dividend Payout Ratio measures the percentage of the company's earnings paid out as dividends.

AlloVir's Dividend Payout Ratio for the quarter that ended in Dec. 2024 is calculated as

Dividend Payout Ratio	=	Dividends per Share (Q: Dec. 2024 )	/	EPS without NRI (Q: Dec. 2024 )
	=	0	/	-3.655
	=	N/A

2. Dividend Yield % measures how much a company pays out in dividends each year relative to its share price.

AlloVir Dividends per Share Related Terms

Thank you for viewing the detailed overview of AlloVir's Dividends per Share provided by GuruFocus.com. Please click on the following links to see related term pages.

AlloVir Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » AlloVir Inc (NAS:ALVR) » Definitions » Dividends per Share

Comparable Companies

Traded in Other Exchanges

N/A

Address

1661 Massachusetts Avenue, PO Box 44, Lexington, MA, USA, 02420

Website

https://www.allovir.com

AlloVir Inc is a biopharmaceutical company. The company focuses on developing allogeneic T-cell therapies to combat viral diseases. Their proprietary virus-specific T cell VST therapy platform enables the creation of off-the-shelf VSTs, therapy platform allows AlloVir to generate off-the-shelf VSTs designed to restore immunity in patients with T cell deficiencies who are at risk from the life-threatening consequences of viral diseases. This included: (1) posoleucel (ALVR105), an investigational off-the-shelf multi-virus-specific T cell therapy. (2) ALVR106, an allogeneic, off-the-shelf VST therapy candidate developed to target devastating diseases caused by four respiratory viruses. (3) ALVR107, an allogeneic, off-the-shelf VST therapy candidate designed to target hepatitis B (HBV).

Executives

Vikas Sinha	director, 10 percent owner, officer: See Remarks	C/O ALEXION PHARMACUETICALS, INC., 352 KNOTTER DRIVE, CHESHIRE CT 06410
Edward Miller	officer: General Counsel	C/O ALEXION PHARMACEUTICALS, INC, 352 KNOTTER DRIVE, CHESHIRE CT 06410
Brett R Hagen	officer: Chief Accounting Officer	200 TECHNOLOGY SQUARE, 4TH FLOOR, CAMBRIDGE MA 02139
Diana Brainard	director	C/O ALLOVIR, INC., 139 MAIN STREET, SUITE 500, CAMBRIDGE MA 02142
Gilead Sciences Inc	10 percent owner	333 LAKESIDE DR, FOSTER CITY CA 94404
Cintia Piccina	officer: Chief Commercial Officer	60 JUBILEE AVENUE, MILTON PARK, ABINGDON, OXFORDSHIRE X0 X0 OX14 4R
Derek N. Adams	director	ALLOVIR, INC., 1100 WINTER STREET, WALTHAM MA 02451
Van Beek Jeroen B	officer: Chief Commercial Officer	C/O TRICIDA, INC., 7000 SHORELINE COURT, SUITE 201, SOUTH SAN FRANCISCO CA 94080
Ercem Atillasoy	officer: See Remarks	C/O ALLOVIR, INC., 139 MAIN STREET, SUITE 500, CAMBRIDGE MA 02142
David Hallal	director, 10 percent owner, officer: Chief Executive Officer	C/O ALEXION PHARMACEUTICALS, INC, 352 KNOTTER DRIVE, CHESHIRE CT 06410
F2 - Tpo Investments Llc	director, 10 percent owner	C/O SINGER, MCKEON INC., 8 W 38TH ST SUITE 1001, NEW YORK NY 10018
F2 Bioscience Av 2022 Llc	director, 10 percent owner	8 WEST 38TH STREET, SUITE 1001, NEW YORK NY 10018
Capital I 2020 F2	director, 10 percent owner	8 WEST 38TH STREET, SUITE 1001, NEW YORK NY 10018
F2 Mc, Llc	director, 10 percent owner	8 WEST 38TH STREET, SUITE 1001, NEW YORK NY 10018
Globeways Holdings Ii Ltd	director, 10 percent owner	C/O SINGER, MCKEON INC., 8 W 38TH ST. STE. 1001, NEW YORK NY 10018